REPONEX PHARMACEUTICALS A/S: Financial statements 2025
CVR: 30082346
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000. The solvency ratio was 63.6%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -6,570,000
- Equity
- DKK 4,645,000
- Total Assets
- DKK 7,301,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | 0 | -6.6M | 4.6M | - |
| 2024 | 0 | 0 | -11.9M | -8.8M | - |
| 2023 | 0 EUR | 0 EUR | -14.3M EUR | 16.8M EUR | - |
| 2022 | - | - | -10.2M | 17.4M | - |
| 2021 | 0 | 0 | -9.9M | 27.4M | - |
Official annual report
How creditworthy is REPONEX PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 19, 2025, Christian Henrik Tange is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of December 19, 2025, Sebastian Bo Jakobsen has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of August 12, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of August 12, 2025, A/S PSE 17 NR. 1056 has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -11,943,000.
As of April 1, 2025, Sebastian Bo Jakobsen is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of April 1, 2025, Thomas Kaas Selsø has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.